Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MindBio Therapeutics Corp. is making significant strides in the field of psychedelic medicine, having completed early clinical trials with promising results for its proprietary LSD-based treatment for depression, and is now in the midst of Phase 2B trials. The company is also preparing for Phase 3 trials and is considering a dual listing on a senior exchange in the US or Australia to further support its growth. MindBio stands out as a leader on the Canadian Securities Exchange for its advanced stage in clinical trials for psychedelic medicines and is actively engaging with investment groups for potential expansion.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.